The efficacyof the LFN-Trp1-gp100/scFv-mPAC vaccine was assessed inC57Bl/6J immunocompetent mice bearing subcutaneous B16–F10tumors (Figure 7A).Tumor growth was monitored over the entire experiment (Figure 7B). This evidence concerns the gene PMEL and neoplasm.